UNLABELLED: Selective inhibition of oncogenic targets and associated signaling pathways forms the basis of personalized cancer medicine. The clinical success of (V600E)BRAF inhibition in melanoma, coupled with the emergence of acquired resistance, underscores the importance of rigorously validating quantitative biomarkers of treatment response in this and similar settings. Because constitutive activation of BRAF leads to proliferation in tumors, we explored 3'-deoxy-3'-(18)F-fluorothymidine ((18)F-FLT) PET to noninvasively quantify changes in tumor proliferation that are associated with pharmacologic inhibition of (V600E)BRAF downstream effectors and that precede changes in tumor volume. METHODS: Human colorectal cancer (CRC) cell lines expressing (V600E)BRAF were used to explore relationships between upregulation of p27 and phosphorylation of BRAF downstream effectors on small-molecule (V600E)BRAF inhibitor exposure. Athymic nude mice bearing (V600E)BRAF-expressing human CRC cell line xenografts were treated with a small-molecule (V600E)BRAF inhibitor (or vehicle) daily for 10 d. Predictive (18)F-FLT PET was conducted before changes in tumor volume occurred. Correlations were evaluated among PET, inhibition of phosphorylated MEK (p-MEK) and phosphorylated-ERK (p-ERK) by Western blot, tumor proliferation by histology, and small-molecule exposure by matrix-assisted laser desorption/ionization (MALDI) imaging mass spectrometry (IMS). RESULTS: Treatment of CRC cell lines with PLX4720 reduced proliferation associated with target inhibition and upregulation of p27. In vivo, PLX4720 treatment reduced (18)F-FLT uptake, but not (18)F-FDG uptake, in Lim2405 xenografts before quantifiable differences in xenograft volume. Reduced (18)F-FLT PET reflected a modest, yet significant, reduction of Ki67 immunoreactivity, inhibition of p-MEK and p-ERK, and elevated tumor cell p27 protein levels. Both (18)F-FLT PET and (18)F-FDG PET accurately reflected a lack of response in HT-29 xenografts, which MALDI imaging mass spectrometry suggested may have stemmed from limited PLX4720 exposure. CONCLUSION: We used preclinical models of CRC to demonstrate (18)F-FLT PET as a sensitive predictor of response to (V600E)BRAF inhibitors. Because (18)F-FLT PET predicted reduced proliferation associated with attenuation of BRAF downstream effectors, yet (18)F-FDG PET did not, these data suggest that (18)F-FLT PET may represent an alternative to (18)F-FDG PET for quantifying clinical responses to BRAF inhibitors.
UNLABELLED: Selective inhibition of oncogenic targets and associated signaling pathways forms the basis of personalized cancer medicine. The clinical success of (V600E)BRAF inhibition in melanoma, coupled with the emergence of acquired resistance, underscores the importance of rigorously validating quantitative biomarkers of treatment response in this and similar settings. Because constitutive activation of BRAF leads to proliferation in tumors, we explored 3'-deoxy-3'-(18)F-fluorothymidine ((18)F-FLT) PET to noninvasively quantify changes in tumor proliferation that are associated with pharmacologic inhibition of (V600E)BRAF downstream effectors and that precede changes in tumor volume. METHODS:Humancolorectal cancer (CRC) cell lines expressing (V600E)BRAF were used to explore relationships between upregulation of p27 and phosphorylation of BRAF downstream effectors on small-molecule (V600E)BRAF inhibitor exposure. Athymic nude mice bearing (V600E)BRAF-expressing human CRC cell line xenografts were treated with a small-molecule (V600E)BRAF inhibitor (or vehicle) daily for 10 d. Predictive (18)F-FLTPET was conducted before changes in tumor volume occurred. Correlations were evaluated among PET, inhibition of phosphorylated MEK (p-MEK) and phosphorylated-ERK (p-ERK) by Western blot, tumor proliferation by histology, and small-molecule exposure by matrix-assisted laser desorption/ionization (MALDI) imaging mass spectrometry (IMS). RESULTS: Treatment of CRC cell lines with PLX4720 reduced proliferation associated with target inhibition and upregulation of p27. In vivo, PLX4720 treatment reduced (18)F-FLT uptake, but not (18)F-FDG uptake, in Lim2405 xenografts before quantifiable differences in xenograft volume. Reduced (18)F-FLTPET reflected a modest, yet significant, reduction of Ki67 immunoreactivity, inhibition of p-MEK and p-ERK, and elevated tumor cell p27 protein levels. Both (18)F-FLTPET and (18)F-FDG PET accurately reflected a lack of response in HT-29 xenografts, which MALDI imaging mass spectrometry suggested may have stemmed from limited PLX4720 exposure. CONCLUSION: We used preclinical models of CRC to demonstrate (18)F-FLTPET as a sensitive predictor of response to (V600E)BRAF inhibitors. Because (18)F-FLTPET predicted reduced proliferation associated with attenuation of BRAF downstream effectors, yet (18)F-FDG PET did not, these data suggest that (18)F-FLTPET may represent an alternative to (18)F-FDG PET for quantifying clinical responses to BRAF inhibitors.
Authors: Martin Wagner; Ulrike Seitz; Andreas Buck; Bernd Neumaier; Stefan Schultheiss; Markus Bangerter; Martin Bommer; Frank Leithäuser; Edgar Wawra; Gerd Munzert; Sven N Reske Journal: Cancer Res Date: 2003-05-15 Impact factor: 12.701
Authors: Fumin Chang; Linda S Steelman; John G Shelton; John T Lee; Patrick M Navolanic; William L Blalock; Richard Franklin; James A McCubrey Journal: Int J Oncol Date: 2003-03 Impact factor: 5.650
Authors: F Chang; L S Steelman; J T Lee; J G Shelton; P M Navolanic; W L Blalock; R A Franklin; J A McCubrey Journal: Leukemia Date: 2003-07 Impact factor: 11.528
Authors: Ryan B Corcoran; Hiromichi Ebi; Alexa B Turke; Erin M Coffee; Michiya Nishino; Alexandria P Cogdill; Ronald D Brown; Patricia Della Pelle; Dora Dias-Santagata; Kenneth E Hung; Keith T Flaherty; Adriano Piris; Jennifer A Wargo; Jeffrey Settleman; Mari Mino-Kenudson; Jeffrey A Engelman Journal: Cancer Discov Date: 2012-01-16 Impact factor: 39.397
Authors: Kapaettu Satyamoorthy; Gang Li; Michelle R Gerrero; Marcia S Brose; Patricia Volpe; Barbara L Weber; Patricia Van Belle; David E Elder; Meenhard Herlyn Journal: Cancer Res Date: 2003-02-15 Impact factor: 12.701
Authors: Klaus Strobel; Jeannine Skalsky; Hans C Steinert; Reinhard Dummer; Thomas F Hany; Ujwal Bhure; Burkhardt Seifert; Marisol Pérez Lago; Helen Joller-Jemelka; V Kalff Journal: Dermatology Date: 2007 Impact factor: 5.366
Authors: James Tsai; John T Lee; Weiru Wang; Jiazhong Zhang; Hanna Cho; Shumeye Mamo; Ryan Bremer; Sam Gillette; Jun Kong; Nikolas K Haass; Katrin Sproesser; Ling Li; Keiran S M Smalley; Daniel Fong; Yong-Liang Zhu; Adhirai Marimuthu; Hoa Nguyen; Billy Lam; Jennifer Liu; Ivana Cheung; Julie Rice; Yoshihisa Suzuki; Catherine Luu; Calvin Settachatgul; Rafe Shellooe; John Cantwell; Sung-Hou Kim; Joseph Schlessinger; Kam Y J Zhang; Brian L West; Ben Powell; Gaston Habets; Chao Zhang; Prabha N Ibrahim; Peter Hirth; Dean R Artis; Meenhard Herlyn; Gideon Bollag Journal: Proc Natl Acad Sci U S A Date: 2008-02-19 Impact factor: 11.205
Authors: Helen Davies; Graham R Bignell; Charles Cox; Philip Stephens; Sarah Edkins; Sheila Clegg; Jon Teague; Hayley Woffendin; Mathew J Garnett; William Bottomley; Neil Davis; Ed Dicks; Rebecca Ewing; Yvonne Floyd; Kristian Gray; Sarah Hall; Rachel Hawes; Jaime Hughes; Vivian Kosmidou; Andrew Menzies; Catherine Mould; Adrian Parker; Claire Stevens; Stephen Watt; Steven Hooper; Rebecca Wilson; Hiran Jayatilake; Barry A Gusterson; Colin Cooper; Janet Shipley; Darren Hargrave; Katherine Pritchard-Jones; Norman Maitland; Georgia Chenevix-Trench; Gregory J Riggins; Darell D Bigner; Giuseppe Palmieri; Antonio Cossu; Adrienne Flanagan; Andrew Nicholson; Judy W C Ho; Suet Y Leung; Siu T Yuen; Barbara L Weber; Hilliard F Seigler; Timothy L Darrow; Hugh Paterson; Richard Marais; Christopher J Marshall; Richard Wooster; Michael R Stratton; P Andrew Futreal Journal: Nature Date: 2002-06-09 Impact factor: 49.962
Authors: Sara Rapic; Christel Vangestel; Jeroen Verhaeghe; David Thomae; Patrick Pauwels; Tim Van den Wyngaert; Steven Staelens; Sigrid Stroobants Journal: Mol Imaging Biol Date: 2017-02 Impact factor: 3.488
Authors: Zhoulei Li; Ken Herrmann; Sabine Pirsig; Kathrin Philipp-Abbrederis; Martin Henninger; Michaela Aichler; Annette Feuchtinger; Axel Walch; Ambros J Beer; Ingo Ringshausen; Kelsey L Pomykala; Klemens Scheidhauer; Markus Schwaiger; Ulrich Keller; Andreas K Buck Journal: Am J Nucl Med Mol Imaging Date: 2013-12-15
Authors: Michael L Schulte; Matthew R Hight; Gregory D Ayers; Qi Liu; Yu Shyr; M Kay Washington; H Charles Manning Journal: Mol Imaging Biol Date: 2017-06 Impact factor: 3.488
Authors: Yiu-Yin Cheung; Michael L Nickels; Eliot T McKinley; Jason R Buck; H Charles Manning Journal: Appl Radiat Isot Date: 2014-12-15 Impact factor: 1.513
Authors: Matthew R Hight; Yiu-Yin Cheung; Michael L Nickels; Eric S Dawson; Ping Zhao; Samir Saleh; Jason R Buck; Dewei Tang; M Kay Washington; Robert J Coffey; H Charles Manning Journal: Clin Cancer Res Date: 2014-02-26 Impact factor: 12.531
Authors: Jennifer G Whisenant; J Oliver McIntyre; Todd E Peterson; Hakmook Kang; Violeta Sánchez; H Charles Manning; Carlos L Arteaga; Thomas E Yankeelov Journal: Mol Imaging Biol Date: 2015-02 Impact factor: 3.488
Authors: Ingfrid S Haldorsen; Mihaela Popa; Tina Fonnes; Njål Brekke; Reidun Kopperud; Nicole C Visser; Cecilie B Rygh; Tina Pavlin; Helga B Salvesen; Emmet McCormack; Camilla Krakstad Journal: PLoS One Date: 2015-08-07 Impact factor: 3.240